Description[edit]

Dr. Chin is the scientific founder of Metamark. Dr. Chin is a Professor of Dermatology at the Harvard Medical School. At Dana-Farber Cancer Institute and Harvard, Dr. Chin is the Scientific Director of Dana-Farber’s Belfer Institute for Applied Cancer Science and co-leads the DF/HCC Melanoma Program and the Harvard Skin SPORE. At the Broad Institute of Harvard and MIT, Dr. Chin is PI of a TCGA Genome Data Analysis Center. Dr. Chin received her M.D. from the Albert Einstein College of Medicine in 1993. She is a board-certified dermatologist and conducted her clinical and scientific training at Columbia Presbyterian Medical Center and the Albert Einstein College of Medicine where she served as Chief Resident of Dermatology. In addition to her many contributions in the area of melanoma genetics and modeling, Dr. Chin focuses on comparative oncogenomics of mouse and human cancers, and integration of functional genetic approaches to accelerate the translation of genomic insights into clinical endpoints. Dr. Chin is actively involved in The Cancer Genes Atlas (TCGA) Project, a member of its Executive Subcommittee, and chairs the GBM and Melanoma Disease Working Groups that interface the genomic science within TCGA with basic and translational biology in the broader community. She is also a member of the Scientific Steering Committee of the International Cancer Genome Consortium. Dr. Chin co-founded AVEO Pharmaceuticals in 2002, a cancer biotechnology company that emphasizes cancer biology.

Innovation[edit]

Activities[edit]